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Abstract 
 
A series of 2,5-disubstituted-3-phenyl-1,2-dihydro-1,2,4-triazin-6(5H)-one derivatives (13(a-g), 18(a-g), 21(a1-a5), 
21b) were synthesized using appropriate synthetic route and characterized by spectral data. Synthesized compounds 
were evaluated for their antimalarial and antimicrobial activities. In vitro antimalarial activity was evaluated against 
chloroquine-sensitive (3D-7) strains of Plasmodium falciparum by using chloroquine and quinine as standard drung. 
For antimicrobial activity compounds were tested against four bacteria (Escherichia coli,Pseudomonas aeruginosa, 
Staphylococcus aureus, Streptococcus pyogenes) and three fungi(Candida albicans, Aspergillus niger, Aspergillus 
clavatus)using gentamicin, ampicillin, chloramphenicol, ciprofloxacin, norfloxacin and nystatin, griseofulvin as 
standard drugs, respectively.  
 
Keywords: Triazinone; pyrazole; antibacterial; antifungal; antimalarial; oxazolone; hydrazides. 
Introduction 
 
 
Microbial infections have increased dramatically in 
recent years. Microbes have been the cause of some of 
the most lethal diseases and widespread pandemic in 
human civilization [1]. Control of deadly infectious 
diseases is seriously threatened by multidrug 
emergence and dissemination of resistant pathogenic 
microbes. The issue is of serious consideration in the 
developing countries. Malaria is a mosquito born 
serious endemic disease caused by protozoa that 
growing over 100 countries. Multidrug resistant 
Plasmodium falciparum is the most common parasite 
and a serious health concern to health care specifically 
in tropical and sub-tropical areas. Therefore, it is an 
ongoing effort to synthesize new antimicrobial and 
antimalarial agents. In chemotherapeutic point of view, 
the search for a molecule having manifold targetswith 
variety of heterocyclic nucleus has always been a very 
attractive approach for researchersas an antimicrobial 
and antimalarial agent[2-5].  
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Furthermore, a wide range of chemotherapeutic 
activities have been ascribed to triazine derivatives 
including antibacterial, antifungal[6-17], antitumor 
[18,19], antiproliferative [20],anticancer [21-50], 
neuro-protective [51], antidepressant [52], 
anticonvulsant [53-60], neuroleptic [61, 62], nootropic 
[63], anti-HIV [64-68],  anti-inflammatory [25, 69-74], 
analgesic [75], antihypertensive [76-78], cardiotonic 
[79], antihistaminergic [80], tuberculostatic [81], 
antiviral [82], estrogen receptor modulators [83], 
cyclin-dependent kinase inhibitors [84-86], antimalarial 
[87-98], and antiparasitic activities [99]potential of 
triazine-pyrazole derivatives [100] and triazine-furan 
derivatives [101-102]with hydrazides. Motivated by 
these facts, we were interested to synthesize and 
investigate the in vitro antimicrobial and antimalarial 
activities of some novel substituted fused heterocyclic 
ring systems namely; 2,5-disubstituted-3-phenyl-1,2-
dihydro-1,2,4-triazin-6(5H)-one derivatives.  Such 
targeted compounds were designed to hybridize the 
triazine ring with the pyrazole/furan and hydrazide 
moieties hoping to obtain synergistic antimicrobial 
activities.As part of our ongoing program directed 
towards the synthesis and evaluation of novel 
compounds of biological interest containing the 
pyrazole/ furan and the triazinone moieties, we have 
reported the synthesis of triazinones which are flexible 
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key intermediates for the synthesis of biologically 
active compounds. In our present work, we highlight 
the synthesis of 2,5-disubstituted-3-phenyl-1,2-
dihydro-1,2,4-triazin-6(5H)-one derivatives with their 
antibacterial, antifungal and antimalarial activities. The 
structures of the newly synthesized compounds were 
confirmed by FT-IR, 1H-NMR, 13C-NMR and Mass 
spectroscopy.Biological screenings of thesynthesized 
heterocyclic system contain the 1,2,4-triazine 
moietygave quite interesting results, especially, due to 
their core structures. All the synthesized compounds 
were screened for their antimicrobial activity against 
four bacteria (Escherichia coli,Pseudomonas 
aeruginosa, Staphylococcus aureus, Streptococcus 
pyogenes) and three fungi(Candida albicans, 
Aspergillus niger, Aspergillus clavatus) using 
gentamicin, ampicillin, chloramphenicol, ciprofloxacin, 
norfloxacin and nystatin, griseofulvin as standard 
drugs, respectively. Antimalarial activity of 
synthesized compounds was screened against 
chloroquine-sensitive (3D-7) strains ofPlasmodium 
falciparumby using chloroquine and quinine as 
standard drug. 
Chemistry 
 
2,5-disubstituted-3-phenyl-1,2-dihydro-1,2,4-triazin-
6(5H)-one derivatives (13(a-g), 18(a-g), 21(a1-21a5)& 
21b) were synthesized as presented in Scheme 2, 3, 4 
by refluxing substituted-2-phenyloxazol-5(4H)-one and 
hydrazine derivatives, which in turn were synthesized 
from the acid via its esterification followed by its 
nucleophilic substitution reaction i.e. hydrazinolysis 
with hydrazine hydrate. Substituted-2-phenyloxazol-
5(4H)-one derivatives were synthesized from the 
hippuric acid & substituted aromatic aldehyde by 
Erlenmeyer Plochl azalactone synthesis while hippuric 
acid was synthesized from glycine by Schottene-
Baumann benzoylation reaction. The compounds were 
recrystallized from ethanol. Thin layer chromatography 
(TLC) was run throughout the reactions to optimize the 
reactions for purity and completion. Spectral data IR, 
1H-NMR, of all the synthesized compounds and 13C-
NMR, and HRMS spectra of selected compounds were 
recorded and found in full agreement with the proposed 
structures. The physicochemical data for the newly 
synthesized compounds are presented in Table 1.  
 
Scheme 1 
HO Ar
O
O Ar
O
C2H5
H2NHN Ar
O
(6a-6i) (7a-7i) (8a-8i)
I II
 
Reagents and conditions: I:Absoluteethanol, conc. H2SO4, refluxfor 10-12 h; II: Absolute ethanol, hydrazine 
hydrate, refluxfor10-12 h. 
 
Table 1:Substituted acid hydrazide synthesized by Scheme 1 (8a-8e) 
 
 
 
 
 
Compound No. Ar 
6a, 7a, 8a p-NO2-phenyl 
6b, 7b, 8b p-OH-phenyl 
6c, 7c, 8c 3,5-dinitrophenyl 
6d, 7d, 8d Phenyl 
6e, 7e, 8e Naphthyl 
6f, 7f, 8f p-CH3-phenyl 
6g, 7g, 8g p-Cl-phenyl 
6h, 7h, 8h 2-pyridyl 
6i, 7i, 8i p-OCH3-phenyl 
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Scheme 2 
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Reagents and conditions: I: Phenyl hydrazine, reflux at 110-120 ˚C for 12 h; II: DMF, POCl3, reflux at 50 ˚C for 10-
15 h; III: hippuric acid, acetic anhydride, anhydrous CH3COONa, melt, heat for 2 h on water bath; IV: substituted 
acid hydrazide (8a-8e)/phenyl hydrazine/hydrazine hydrate,anhydrous CH3COONa, glacial acetic acid, reflux for 8-
10 h. 
 
Table 2:  2,5-Disubstituted-3-phenyl-1,2-dihydro-1,2,4-triazin-6(5H)-one derivatives synthesized by Scheme 2 
(13a-13g) 
S. No. Compound No. Hydrazide used Ar R 
1. 13a 8a 
R
O
 
p-NO
2
-phenyl 
2. 13b 8b 
R
O
 
p-OH-phenyl 
3. 13c 8c 
R
O
 
3,5-dinitro-phenyl 
4. 13d 8d 
R
O
 
Phenyl 
5. 13e 8e 
R
O
 
Naphthyl 
6. 13f 8f 
R
O
 
p-CH3-phenyl 
7. 13g 8g 
R
O
 
p-Cl-phenyl 
8. 13h 8h 
R
O
 
2-pyridyl 
9. 13i 8i 
R
O
 
p-OCH3-phenyl 
10. 13j Phenyl hydrazine phenyl - 
11. 13k Hydrazine hydrate -H - 
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Scheme 3  
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Reagents and conditions: (I) Phenyl hydrazine, ethanol, glacial acetic acid, reflux; (II) DMF, POCl3, reflux at 50 ˚C 
for 10-15 h; (III) hippuric acid, acetic anhydride, anhydrous CH3COONa, melt, heat for 2 h on water bath; (IV): 
substituted acid hydrazide (8a-8e)/phenyl hydrazine/hydrazine hydrate, anhydrous CH3COONa, glacial acetic acid, 
reflux, for 8-10 h. 
 
Table: 3: 2,5-Disubstituted-3-phenyl-1,2-dihydro-1,2,4-triazin-6(5H)-one derivatives synthesized by Scheme 3 
(18a-18g) 
S.No. Compound No. Hydrazide 
used 
Ar R 
1. 18a 8a 
R
O
 
p-NO2-phenyl 
2. 18b 8b 
R
O
 
p-OH-phenyl 
3. 18c 8c 
R
O
 
3,5-dinitro-phenyl 
4. 18d 8d 
R
O
 
phenyl 
5. 18e 8e 
R
O
 
naphthyl 
6. 18f Phenyl 
hydrazine 
phenyl 
 
- 
7. 18g Hydrazine 
hydrate 
-H - 
 
Scheme 4 
Ar'-CHO N
O
O
Ar'
N
N
H
N
Ar
O
O
Ar'
(19a, 19b) (20a, 20b) (21a1 - 21a5, 21b)
I II
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Reagents and conditions: (I)Hippuric acid, acetic anhydride, anhydrous CH3COONa, melt, heat for 2 h on water 
bath; XII: substituted acid hydrazide (8a-8e), anhydrous CH3COONa, glacial acetic acid, reflux, for 8-10 h. 
Table: 4:2,5-Disubstituted-3-phenyl-1,2-dihydro-1,2,4-triazin-6(5H)-one derivatives synthesized by Scheme 4 
(21a1-21a5, 21b). 
S.No Compound No. Hydrazide used Ar’ Ar 
1. 19a, 20a - 
 
- 
2. 19b, 20b - 
 
- 
3. 21a1 8a 
 
p-NO
2
-phenyl 
4. 21a2 8b 
 
p-OH-phenyl 
5. 21a3 8c 
 
3,5-dinitro-phenyl 
6. 21a4 8d 
 
Phenyl 
7. 21a5 8e 
 
Naphthyl 
8 21b 8e 
 
Naphthyl 
 
Biological assay 
Antimicrobial susceptibility assay 
Broth micro-dilution method: A quantitative assay 
method is mainly used to determine the minimum 
inhibitory concentration (MIC) of antimicrobial 
agents/antibiotics that inhibit or kill the 
microorganisms. 
Minimum Inhibitory Concentration: The minimum 
concentration of antibiotic that inhibit growth of 
microorganism after overnight incubation, and 
minimum bactericidal concentrations (MBCs) as the 
lowest concentration of antimicrobial that will prevent 
the growth of an organism after subculture on to 
antibiotic-free media. A 96 well tissue culture micro 
plate was used, for the experiment, which is based on 
serial   dilution, first 10 wells of the row were used for 
serial dilution of chosen compounds, 11th was kept as 
positive control whereas 12th was left as media control. 
❖ 150µl of liquid media (nutrient/sabouraud 
dextrose broth) was added in the well of one 
column then 3µl of antibiotics and constituents 
to be tested were added from the stock of 100 
mg/ml, 20 mg/ml to achieve 1 mg/ml of 
concentration in first row wells, it was mixed 
properly and then volume was made to 300µl by 
addition of 147µl media. 
❖ 150µl of media containing extracts/constituents 
was added to subsequent wells, same   were 
repeated till 10th well column remained were 
discarded. 
❖ 10µl of working culture suspension of 
bacteria/fungi were added to the entire well 
except media control. 
❖ The plates were incubated at 37ºC overnight for 
antimicrobial activity whereas for anti- fungal 
activity it was incubated for 48 h at 28ºC. 
Growth was indicated by turbidity and MIC were 
determined and expressed as µg/ml, absence of 
turbidity was noted as MIC; viability microbes in 
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particular well was also confirmed by addition of 
p-iodonitrotetrazolium violet (INT;0.2 mg/ml)dye. 
 
Chemistry 
Present study was undertaken to synthesize some novel 
1,2,4-triazine derivatives. All the synthesized 
compounds were subjected for their antimicrobial and 
anti-malarial evaluation. The target compounds (13(a-
g), 18(a-g), 21(a1-21a5), 21b)were synthesized by four 
step procedure represented inScheme 2,3,4.First step in 
Scheme 2 involves the formation of compound (10)by 
the reaction of ethyl acetoacetate with phenyl 
hydrazineon refluxing. Subsequently, compound 
(10)on reaction with phosphorus oxychloride (POCl3) 
reflux in presence of dimethyl formamide (DMF) 
yieldcompound (11) on refluxing. Compound 
(11)reacted with hippuric acid and acetic anhydride in 
presence of sodium acetate anhydrous yield compound 
(12). Finally, compound (12)reacted withappropriate 
substituted acid hydrazide by refluxing in glacial acetic 
acid in presence of sodium acetate anhydrous to form 
2,5-disubstituted-3-phenyl-1,2-dihydro-1,2,4-triazin-6 
(5H) -one derivatives (13(a-g). In Scheme 3, compound 
(15) formed by reaction of acetophenone and phenyl 
hydrazine on refluxing. Compound (15) reflux with 
POCl3 and DMF yields compound (16) which on 
reaction with hippuric acid and acetic anhydride in 
presence of sodium acetate anhydrous yield compound 
(17). Finally, compound (17) reacted with appropriate 
substituted acid hydrazide by refluxing in glacial acetic 
acid in presence of sodium acetate anhydrous to form 
2,5-disubstituted-3-phenyl-1,2-dihydro-1,2,4-triazin-6 
(5H) -one derivatives (18(a-g).In Scheme 4, 
compounds 19a and 19b on reaction with hippuric acid 
and acetic anhydride in presence of sodium acetate 
anhydrous yield compounds (20a and 20b), 
respectively. Compounds (20a and 20b) reacted with 
appropriate substituted acid hydrazide by refluxing in 
glacial acetic acid in presence of sodium acetate 
anhydrous to form 2,5-disubstituted-3-phenyl-1,2-
dihydro-1,2,4-triazin-6 (5H) -one derivatives 21(a1-
21a5), 21b), respectively. All the compounds in solid 
state showed sharp melting points. The compounds 
were stable and soluble in DMSO, methanol 
andchloroform. All the synthesized compounds were 
characterized by IR, 1H NMR, 13C NMR, and Mass 
spectroscopy. Characteristic IR bands provide 
significant indication for the formation of compounds 
(8(a-e), 13(a-g), 18(a-g), 21(a1-21a5), 21b). The sharp 
melting point at 116-120 °C and 106 °C provide strong 
information about the formation of compound (10 and 
15), respectively. The formation of compound (11)was 
confirmed by the presence of band at/or around 1674 
cm-1 (C=O), 1593 cm-1(C=N), 1523 cm-1 (C=C) and at 
763 cm-1 (C-Cl). The compound (16) was confirmed by 
the presence of band at/or around 3121, 3024 
(Aromatic C-H stretching), 1666 (C=O), 1613 (C=N), 
1593 (C=C). The appearance of characteristic band 
at/or 1797 cm-1, 1610 cm-1,1585 cm-1, 694 cm-1due to 
Azalactone, C=N, C=C and C-Cl respectively strongly 
favor the formation of compound (12).The presence of 
characteristic band at/or 1784 (C=O, Azalactone), 1597 
(C=N), 1555 (C=C) and 1789 (C=O, Azalactone), 1596 
(C=N), 1555 (C=C) confirms the formation of 
compounds (20a and 20b), respectively. The 
disappearance of bands at around 1797 cm-1 and 
appearance of bands at 3310-3229 cm-1, 1723-1704 cm-
1, 1693-1638 cm-1, 1597-1611 cm-1, 1537-1580 cm-1 
due to N-H (stretching),CO and C6=O, C=N and C=C 
respectively confirms the formation of compounds 
(13(a-g), 18(a-g), 21(a1-21a5), 21b).The appearance of 
characteristic band at/or 1789 cm-1, 1597 cm-1, 1556 
cm-1 due to Azalactone, C=N and C=C respectively 
strongly favor the formation of compound (17).  
Further confirmation of all the synthesized compounds 
was done using 1H NMR spectroscopic data. 
Appearance of a singlet at9.98 ppm and 2.83 ppm due 
to CHO and CH3 proton, respectively, provides strong 
confirmation of the compound (11). Structure of 
compound (12)was confirmed by the absence of peak 
at 9.98 ppm due to CHO proton and also by the 
appearance of a singlet at 7.23 ppm due to CH=C 
proton. Structural confirmation of final compounds was 
achieved by the presence of singlet at 10.58 ppm due to 
CONH proton. The 13C NMR spectra of final 
compounds showed some prominent signals, such as 
signals at 170.27 ppm, 164.28 ppm, 157.08 ppm, 
151.53 ppm and 150.20 ppm due to presence of C=O, 
C6, C3, C-NO2 and C-CH3 respectively and provide 
strong recommendation for the formation of these 
compounds (13(a-g), 18(a-g), 21(a1-21a5), 21b). Other 
peaks were also present in the NMR spectra of these 
compounds at their usual positions described in the 
experimental section. 
 
Antibacterial activity 
All the synthesized compounds (13(a-g), 18(a-g), 
21(a1-21a5), 21b)were screened for their in vitro 
antimicrobial activity using the Gram-positive, Gram-
negativebacteria and fungi. Four different cultures, two 
each of Gram-negative (Escherichia coli and 
Pseudomonas aeruginosa) and Gram-positive 
(Staphylococcus aureus, Streptococcus pyogenes)were 
treated with the synthesized compounds (13(a-g), 18(a-
g), 21(a1-21a5), 21b)using broth micro dilution method. 
In vitro antimalarial activity of all the compounds was 
evaluated against chloroquine-sensitive (3D-7) strains 
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of Plasmodium falciparumby using chloroquine and quinine as standard drung.  
 
Table: 5: In vitroAntibacterial activity (MIC, μg/mL) of compounds (13(a-g), 18(a-g), 21(a1-21a5), 21b) 
 
 
S. No. 
 
 
Code No. 
Gram Positive Gram Negative 
S. Aureus 
MTCC 96 
S. Pyogenes 
MTCC 443 
E. Coli 
MTCC 442 
P. Aeruginosa 
MTCC 441 
1. 13a 250 200 125 125 
2. 13b 100 250 200 125 
3. 13c 100 125 250 250 
4. 13d 200 200 250 200 
5. 13e 100 250 125 250 
6. 13f 200 250 250 200 
7. 13g 100 250 100 100 
8. 18a 100 100 62.5 200 
9. 18b 125 250 100 250 
10. 18c 62.5 62.5 100 100 
11. 18d 62.5 250 250 250 
12. 18e 200 500 200 200 
13. 18f 250 200 125 100 
14. 18g 200 250 100 125 
15. 21a1 62.5 250 250 250 
16. 21a2 200 125 125 100 
17. 21a3 250 100 200 100 
18. 21a4 100 125 200 200 
19. 21a5 200 125 100 62.5 
20. 21b 500 500 62.5 125 
 Gentamycin 0.25 0.5 0.05 1 
 Ampicillin 250 100 100 - 
 Chloramphenicol 50 50 50 50 
 Ciprofloxacin 50 50 25 25 
 Norfloxacin 10 10 10 10 
 
Table: 6: In vitro Antifungal activity (MIC, μg/mL) of compounds (13(a-g), 18(a-g), 21(a1-21a5), 21b) 
 
 
S. No. 
 
 
Code No. 
Fungi 
C. albicans 
MTCC 227 
A. niger MTCC 
282 
A. clavatus MTCC 
1323 
1. 13a 1000 1000 1000 
2. 13b 500 >1000 >1000 
3. 13c >1000 250 500 
4. 13d >1000 500 500 
5. 13e 250 >1000 >1000 
6. 13f 500 >1000 >1000 
7. 13g 1000 >1000 >1000 
8. 18a 1000 500 500 
9. 18b >1000 >1000 >1000 
10. 18c 1000 500 500 
11. 18d 1000 500 1000 
12. 18e >1000 1000 1000 
13. 18f 500 500 1000 
14. 18g 1000 500 500 
15. 21a1 500 1000 >1000 
16. 21a2 500 >1000 >1000 
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17. 21a3 250 1000 1000 
18. 21a4 250 250 500 
19. 21a5 250 500 500 
20. 21b 1000 500 500 
 Nystatin 100 100 100 
 Greseofulvin 500 100 100 
 
Table: 7: In vitroAntimalarial activity of compounds ((13(a-g), 18(a-g), 21(a1-21a5), 21b)) against Plasmodium 
falciparum (3D-7) 
 
 
 
S. No. 
 
 
Code No. 
IC50 (μg/mL) 
Plasmodium falciparum  
(3D-7) 
1. 13a 0.98 
2. 13b 1.13 
3. 13c 1.20 
4. 13d 0.88 
5. 13e 0.93 
6. 13f 0.97 
7. 13g 1.13 
8. 18a 0.98 
9. 18b 0.96 
10. 18c 0.91 
11. 18d 0.90 
12. 18e 0.95 
13. 18f 0.92 
14. 18g 0.91 
15. 21a1 1.07 
16. 21a2 1.16 
17. 21a3 1.00 
18. 21a4 0.85 
19. 21a5 0.90 
20. 21b 0.95 
 Chloroquine 0.02 
 Quinine 0.27 
 
Results and discussions 
 
The twenty 1,2,4-triazin-6(5H)-one derivatives (13(a-
g), 18(a-g), 21(a1-21a5), 21b) were synthesized in 
good yield. The structures of these compounds were 
confirmed by IR, 1H-NMR, 13C-NMR and mass 
analysis. The synthesized compounds were evaluated 
for their antimicrobial and antimalarial activity. Out of 
the synthesized compounds thirteen analogues have 
shown MIC in the range of 100–200 μg/mL. 
Compounds 18c, 18d and 21a1 exhibited excellent 
activity and 13b, 13c, 13e, 13g, 18a and 21a4 
compounds exhibited good activity against S. Aureus 
as compared to Ampicillin (MIC= 250 μg/mL). 
Compound 18c exhibited excellent activity at 62.5 
μg/mL and 18a and 21a3 exhibited good activity at 100 
μg/mL against S. Pyogenesas compared to Ampicillin 
(MIC= 100 μg/mL). Compounds 18a and 21b showed 
excellent activity at 62.5 μg/mL and 13g, 18b, 18c, 18g 
and 21a5 exhibited good activity at 100 μg/mLagainst 
E. Coli as compared to Ampicillin (MIC= 100 μg/mL). 
Compounds 13g, 18c, 18g, 21a2, 21a3 and 21a5 
exhibited good activity at 62.5-100μg/mL against P. 
Aeruginosa as compared to Chloramphenicol (MIC= 
50 μg/mL). Most of the compounds showed very good 
antifungal activity against Candida albicans, their MIC 
values were in the range between (250-500 μg/mL). 
Compounds 13e, 21a3, 21a4 and 21a5 showed 
excellent activity at 250 μg/mL and compounds 13b, 
13f, 18f, 21a1 and 21a2 showed average activity at 500 
μg/mL against C. albicans as compared to Griseofulvin 
(MIC= 500 μg/mL). Whereas 13c compound showed 
good activity against Aspergillus Niger as compared to 
Griseofulvin and Nystatin (MIC= 100 μg/mL). Some 
compounds showed good antimalarial activity at 0.88-
0.98 μg/mL against Plasmodium falciparum as 
compared to quinine. Thus, the existence of aromaticity 
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and lipophilicity found to have strong significance to 
the antimicrobial and antimalarial activity. 
 
Conclusion 
 
In this article, we have report a series of 1,2,4-triazin-
6(5H)-one derivatives showing better activity. All the 
synthesized compounds have been established by IR, 
1H NMR and 13C-NMR and mass spectral data. In 
conclusion, the potency and selectivity of synthesized 
compounds against standard drugs make them effective 
leads for new research in future that possess better 
activity antimicrobial and antimalarial chemotherapy. 
These new molecules are very useful for more 
optimization effort in microbial and protozoal 
chemotherapy. 
 
Experimental 
 
Chemistry 
 
All the chemicals used were laboratory grade and 
procured from E. Merck (Germany), S.D. Fine 
Chemicals, Rankem and Spectrochem Pvt. Ltd. (India). 
Melting points were determined by open glass capillary 
tube and are uncorrected. Thin layer chromatography 
(TLC) plates were used to confirm the purity of 
commercial reagents used, compounds synthesized and 
to monitor the reactions as well. Two different solvent 
systems; toluene: ethyl acetate: formic acid (5:4:1) and 
ethyl acetate: hexane (0.5:9.5), were used to run the 
TLC. The spots were located under iodine vapors/UV 
light. IR spectra were obtainedin the region 4000-400 
cm-1 range using potassium bromide (KBr) discs on 
Nicolet 380 FT-IR. The proton nuclear magnetic 
resonance 1H-NMR, 13C-NMR and mass spectra of a 
few compounds were recorded on Bruker Avance II 
400 NMR spectrometer & Bruker model DRX-300 
NMR spectrometer-using TMS as internal standard in 
DMSO-d6/CDCl3.  The ESI-MS spectrums were 
recorded on a Waters Micromass Q-TOF Micro Mass 
Spectrometer. 
Synthesis of 3-methyl-1-phenyl-2-pyrazolin-5-one 
(10) [103-106]:A mixture of (0.1mol) ethyl 
acetoacetate (4) and (0.1mol) phenylhydrazine was 
refluxed in RBF at 110-120 ˚C for 12 h. After cooling 
the reaction mixture, diethyl ether was added with 
stirring to obtain the solid product. Washed the crude 
product with diethyl ether and further with water. After 
drying, it was recrystallized with ethanol to obtain pure 
crystals as a pale yellow crystalline compound. Yield: 
73%; m.p.:116-120 ˚C; Rf:0.58 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). 
Synthesis of acetophenone phenylhydrazone (15) 
[107,108]:Reflux a mixture of (0.1 mol) acetophenone 
(9) and (0.1 mol) phenylhydrazine with 60 mL of 
ethanol and a few drops of glacial acetic acid. The 
crude product so obtained on cooling was recrystallised 
from ethanol to obtain a pure acetophenone 
phenylhydrazone as a white solid. Yield: 76%; m.p.: 
106 ˚C; Rf:0.76 (Ethyl acetate: Hexane (0.5:9.5)). 
 
Procedure for synthesis of 5-chloro-3-methyl-1-
phenyl-1H-pyrazole-4-carboxaldehyde (11) 
[109]:Phosphorous oxy chloride was added dropwise 
with stirring in dry di-methyl formamide placed at 0 
˚C. The solution was stirred at the same temperature. 
After two hours 3-methyl-1-phenyl-2-pyrazolin-5-one 
was added in the solution and again stirred for one hour 
at 50 ˚C. Then the solution was refluxed for 10-15 h. 
Poured the solution in to the crushed ice with stirring 
and neutralized with saturated solution of sodium 
bicarbonate. The crude product so obtained was filtered 
and washed with water. It was further recrystallized 
from ethanol and desired compound obtained as brown 
needles. Yield: 62.5%; m.p.: 140-144 ˚C; Rf:0.71 
(Toluene: Ethyl acetate: Formic acid (5: 4: 1)). IR νmax 
(cm−1): 3053 (Aromatic C-H stretching), 2921 
(Aliphatic C-H stretching), 1674 (C=O), 1593 (C=N), 
1523 (C=C), 763 (C-Cl). 1H-NMR (300 MHz, CDCl3): 
δ (ppm) 9.98 (s, 1H, CHO), 7.56-7.47 (m, 5H, Ar-H) 
2.83 (s, 3H, CH3). 
Procedure for synthesis of 1,3-diphenyl-1H-
pyrazole-4-carbaldehyde (16) [110]:Phosphorous oxy 
chloride was added dropwise with stirring in dry di-
methyl formamide placed at 0 ˚C. The solution was 
stirred at the same temperature. After two hours 
acetophenone phenylhydrazone was added in the 
solution and again stirred for one hour at 50 ˚C. Then 
the solution was refluxed for 10-15 h. Poured the 
solution in to the crushed ice with stirring and 
neutralized with saturated solution of sodium 
bicarbonate. The crude product so obtained was filtered 
and washed with water. It was further recrystallized 
from ethanol and desired compound obtained as brown 
needles. Yield: 70%; m.p.: 138-140 ˚C; Rf: 0.39 
(Toluene: Ethyl acetate: Formic acid (5:4:1)). IR νmax 
(cm−1): 3121, 3024 (Aromatic C-H stretching), 1666 
(C=O), 1613 (C=N), 1593 (C=C). 1H-NMR (400 MHz, 
CDCl3): δ (ppm) 10.05 (1s, 1H, CHO), 8.54 (1s, 1H, 
C5-H), 7.83-7.77 (m, 4H, Ar-H), 7.53-7.41 (m, 5H, Ar-
H), 7.41-7.38 (t, 1H, Ar-H). 
Procedure for the synthesis of 4-((5-chloro-3-
methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-2-
phenyloxazol-5(4H)-one (12) [111]:A mixture of 5-
chloro-3-methyl-1-phenyl-1H-pyrazole-4-
carboxaldehyde (0.25 mol), hippuric acid (0.25 mol), 
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acetic anhydride (0.75 mol) and anhydrous sodium 
acetate was taken in a 500 mL conical flask and heated 
on an electric hot plate with constant shaking. As soon 
as the mixture liquefied completely, transferred the 
flask to a water bath and heated for 2 h. Then added 
100 mL of ethanol slowly to the contents of the flask 
and allowed the mixture to stand overnight. Filtered the 
crystalline product with suction and first washed with 
two 25 mL portions of ice-cold alcohol and then 
washed with two 25 mL portions of boiling water & 
dried at 100 ˚C. Yellow solid; Yield: 60%; m.p.: 184-
186 ˚C; Rf: 0.82 (Toluene: Ethyl acetate: Hexane 
(5:4:1)). IRνmax (cm−1): 3053 (Aromatic C-H 
stretching), 2929 (Aliphatic C-H stretching), 1797 
(C=O, Azalactone), 1610 (C=N), 1585 (C=C), 694 (C-
Cl). 1H-NMR (300 MHz, CDCl3): δ (ppm) 8.13-8.10 
(d, 2H, Ar-H), 7.63-7.43 (m, 8H, Ar-H), 7.23 (s, 1H. 
CH=C), 2.79 (s, 3H, CH3).13C-NMR (75 MHz, 
CDCl3): δ (ppm) 167.60 (C=O), 161.96 (C2, 
Azalactone), 151.03 (C3, pyrazole), 137.57 (N1-C), 
133.11, 131.48, 131.02, 129.23, 129.01, 128.84, 
128.04, 125.70, 124.91, 121.91, 114.04, 16.42 (CH3). 
Procedure for the synthesis of 4-[(1,3-diphenyl-1H-
pyrazol-4-yl)methylidene]-2-phenyl-1,3-oxazol-
5(4H)-one (17):A mixture of 1,3-diphenyl-1H-
pyrazole-4-carbaldehyde (0.25 mol), hippuric acid 
(0.25 mol), acetic anhydride (0.75 mol) and anhydrous 
sodium acetate was taken in a 500 mL conical flask 
and heated on an electric hot plate with constant 
shaking. As soon as the mixture liquefied completely, 
transferred the flask to a water bath and heated for 2 h. 
Then added 100 mL of ethanol slowly to the contents 
of the flask and allowed the mixture to stand overnight. 
Filtered the crystalline product with suction and first 
washed with two 25 mL portions of ice-cold alcohol 
and then washed with two 25 mL portions of boiling 
water & dried at 100 ˚C. Orange solid; Yield: 70%; 
m.p.: 110-116 ˚C; Rf: 0.81 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IR νmax (cm−1): 3056 (Aromatic 
C-H stretching), 2917 (Aliphatic C-H stretching), 1789 
(C=O, Azalactone), 1597 (C=N), 1556 (C=C). 1H-
NMR (300 MHz, CDCl3): δ (ppm) 9.23 (s, 1H, C5-H), 
8.19-8.17 (d, 2H, Ar-H), 7.91-7.88 (d, 2H, Ar-H), 7.73-
7.71 (d, 2H, Ar-H), 7.65-7.49 (m, 8H, Ar-H), 7.42-7.38 
(m, 2H, Ar-H, CH=C). 13C-NMR (75 MHz, CDCl3): δ 
(ppm) 167.03 (C=O), 162.19 (C2), 155.25 (C3, 
pyrazole), 139.40 (N1-C1), 137.84 (C4), 133.18, 131.69, 
131.62, 131.42, 129.65, 129.47, 128.98, 128.18, 
127.63, 125.70, 123.59, 119.80, 116.13. 
Procedure for the synthesis of 4-(furan-2-
ylmethylene)-2-phenyloxazol-5(4H)-one (20a):A 
mixture of furfuraldehyde (0.25 mol), hippuric acid 
(0.25 mol), acetic anhydride (0.75 mol) and anhydrous 
sodium acetate was taken in a 500 mL conical flask 
and heated on an electric hot plate with constant 
shaking. As soon as the mixture liquefied completely, 
transferred the flask to a water bath and heated for 2 h. 
Then added 100 mL of ethanol slowly to the contents 
of the flask and allowed the mixture to stand overnight. 
Filtered the crystalline product with suction and first 
washed with two 25 mL portions of ice-cold alcohol 
and then washed with two 25 mL portions of boiling 
water & dried at 100 ˚C.Orange solid; Yield: 80%; 
m.p.: 202-203 ˚C; Rf: 0.80 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IRνmax (cm−1): 3107 (Aromatic C-
H stretching), 2845 (Aliphatic C-H stretching), 1784 
(C=O, Azalactone), 1597 (C=N), 1555 (C=C). 1H-
NMR (300 MHz, CDCl3): δ (ppm) 8.17-8.14 (d, 2H, 2-
furan, Ar-H), 7.68 (s, 1H, CH=C), 7.63-7.49 (m, 5H, 4-
furan, Ar-H), 7.17 (s, 1H, 3-furan).  
Procedure for the synthesis of 4-(4-hydroxy-3-
methoxybenzylidene)-2-phenyloxazol-5(4H)-one 
(20b):A mixture of vanillin (0.25 mol), hippuric acid 
(0.25 mol), acetic anhydride (0.75 mol) and anhydrous 
sodium acetate was taken in a 500mL conical flask and 
heated on an electric hot plate with constant shaking. 
As soon as the mixture liquefied completely, 
transferred the flask to a water bath and heated for 2 h. 
Then added 100 mL of ethanol slowly to the contents 
of the flask and allowed the mixture to stand overnight. 
Filtered the crystalline product with suction and first 
washed with two 25 mL portions of ice-cold alcohol 
and then washed with two 25 mL portions of boiling 
water & dried at 100 ˚C. Yellow solid; Yield: 79%; 
m.p.: 240-242 ˚C; Rf: 0.81 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IRνmax (cm−1): 3100 (Aromatic C-
H stretching), 2845 (Aliphatic C-H stretching), 1789 
(C=O, Azalactone), 1596 (C=N), 1555 (C=C). 1H-
NMR (300 MHz, CDCl3): δ (ppm) 8.14-8.12 (d, 3H, 
Ar-H), 7.64-7.59 (m, 3H, Ar-H, CH=C), 7.55-7.50 (m, 
2H, Ar-H), 7.20 (s, 1H, OH), 7.14- 7.11 (d, 1H, Ar-H), 
3.94 (s, 3H, CH3). 
General procedure for the synthesis of acid 
hydrazide (8a-e)[107, 112]:Aromatic acids were first 
converted to its ester by esterification procedure using 
conc. sulphuric acid as a catalyst in absolute ethanol. 
The mixture of acid, absolute ethanol and conc. 
sulphuric acid were refluxed for 10-12 h, distilled off 
about half of the alcohol on a water bath after this, 
diluted the residue with sufficient quantity of water and 
removed the upper layer of the crude ester and 
extracted the aqueous layer with ether. Later on, 
combined ethereal extract and crude ester were washed 
with water, then with saturated sodium hydrogen 
carbonate solution until effervescence ceased, and 
finally with water. Dried with anhydrous sodium 
sulphate & removed the ether on a water bath. To an 
alcoholic solution of aromatic ester, hydrazine hydrate 
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was added. The resulting reaction mixture was refluxed 
for10-12 h. The excess of alcohol was distilled off and 
cooled. Filtered off, the crystals of acid hydrazide and 
recrytallised from ethanol. The physicochemical data 
of the substituted hydrazine derivatives is given below: 
p-Nitrobenzohydrazide (8a):  White solid; Yield: 
76%; m.p.: 144-146 ˚C; Rf: 0.15 (Toluene: Ethyl 
acetate: Formic acid (5:4:1)). IRνmax (cm−1): 3337 (N-
H, stretching), 3109 (Aromatic C-H stretching), 
3060(Aliphatic C-H stretching), 1650 (C=O), 1597 
(C=N), 1503 (C=C). 
p-Hydroxybenzohydrazide (8b): Off white solid; 
Yield: 70%; m.p.: 258-260 ˚C; Rf: 0.21 (Toluene: Ethyl 
acetate: Formic acid (5:4:1)). IRνmax (cm−1): 3313 (N-
H, stretching), 3198 (Aromatic C-H stretching), 
2802(Aliphatic C-H stretching), 1613 (C=O), 1535 
(C=N), 1503 (C=C). 
 3,5-Dinitrobenzohydrazide (8c): White solid; Yield: 
83%; m.p.: 155-157˚C; Rf: 0.35 (Toluene: Ethyl 
acetate: Formic acid (5:4:1)). IRνmax (cm−1): 3298 (N-
H, stretching), 3123 (Aromatic C-H stretching), 
3046(Aliphatic C-H stretching), 1637 (C=O), 1524 
(C=N), 1424 (C=C). 
Benzohydrazide (8d): White solid; Yield: 65%; m.p.: 
120-122˚C; Rf: 0.29 (Toluene: Ethyl acetate: Formic 
acid (5:4:1)). IRνmax (cm−1): 3310 (N-H, stretching), 
3190 (Aromatic C-H stretching), 2911(Aliphatic C-H 
stretching), 1650 (C=O), 1550 (C=N), 1510 (C=C). 
 2-Naphthohydrazide (8e): Yellow solid; Yield: 85%; 
m.p.: 160-163˚C; Rf: 0.20 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IRνmax (cm−1): 3329 (N-H, 
stretching), 3243 (Aromatic C-H stretching), 
2847(Aliphatic C-H stretching), 1680 (C=O), 1550 
(C=N), 1510 (C=C). 
Synthesis of 5-((5-chloro-3-methyl-1-phenyl-1H-
pyrazol-4-yl)methylene)-2-(4-nitrobenzoyl)-3-
phenyl-1,2-dihydro-1,2,4-triazin-6(5H)-one (13a) 
[113]: An equimolar quantity of (0.01 mol) 4-((5-
chloro-3-methyl-1-phenyl-1H-pyrazol-4-
yl)methylene)-2-phenyloxazol-5(4H)-one, (0.01 mol) 
p-nitrobenzohydrazide and (0.2 g) anhydrous sodium 
acetate in 15 mL glacial acetic acid was refluxed for 8-
10 h. The reaction mixture was poured into crushed ice 
and stirred. The crystals so obtained were filtered, 
washed with water, dried and recrystallized from 
ethanol. Yellow solid; Yield: 36.8 %; m.p.: 242-244 
ºC; Rf: 0.75 (Toluene: Ethyl acetate: Formic acid 
(5:4:1)). IR (KBr) νmax (cm−1): 3273 (N-H stretching), 
3052 (Aromatic C-H stretching), 2933 (Aliphatic C-H 
stretching), 1719 (CONH), 1665 (C6=O), 1609 (C=N, 
imine), 1576 (C=C stretching), 697 (C-Cl).1H-NMR 
(CDCl3): δ (ppm) 10.58 (s, 1H, CONH), 8.17-8.15 (d, 
2H, Ar-H), 7.99-7.92 (m, 4H, Ar-H), 7.60-7.44 (m, 8H, 
Ar-H), 7.37 (s, 1H, CH=C), 2.82 (s, 3H, -CH3). 13C-
NMR (CDCl3): δ (ppm) 170.27 (C=O, benzoyl), 
164.28 (C6), 157.08 (C3), 151.53(C-NO2), 150.20(C-
CH3), 133.78, 132.11, 131.59, 129.24, 129.01, 128.87, 
128.15, 127.51, 124.98, 123.82, 122.75, 114.11, 16.65 
(C-CH3). ESI-MS: m/z= 527.2 (M+, 100%), 529.2 
(M++2, 38%), 530.29 (M++3, 11.5%).   
Synthesis of 5-((5-chloro-3-methyl-1-phenyl-1H-
pyrazol-4-yl)methylene)-2-(4-hydroxybenzoyl)-3-
phenyl-1,2-dihydro-1,2,4-triazin-6(5H)-one (13b): 
An equimolar quantity of (0.01 mol) 4-((5-chloro-3-
methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-2-
phenyloxazol-5(4H)-one (12), (0.01 mol) p-
hydroxybenzohydrazide and (0.2 g) anhydrous sodium 
acetate in 15 mL glacial acetic acid was refluxed for 8-
10 h. The reaction mixture was poured into crushed ice 
and stirred. The crystals so obtained were filtered, 
washed with water, dried and recrystallized from 
ethanol. Orange solid; Yield: 36.8%; m.p.: 226-230 ºC; 
Rf: 0.71 (Toluene: Ethyl acetate: Formic acid (5:4:1)). 
IR (KBr) νmax (cm−1): 3229 (N-H, stretching), 3027 
(Aromatic C-H stretching), 2929 (Aliphatic C-H 
stretching), 1716 (C=O), 1641 (C6=O), 1609 (C=N), 
1580 (C=C), 689 (C-Cl).  1H-NMR (CDCl3) (δ, ppm) 
11.03 (s, 1H, CONH, D2O exchangeable), 8.06-8.04 (d, 
2H, Ar-H), 7.87-7.84 (d, 2H, Ar-H), 7.60-7.58 (d, 2H, 
Ar-H), 7.54-7.40 (m, 6H, Ar-H), 7.21 (s, 1H, CH=C), 
6.91-6.88 (d, 2H, Ar-H), 2.78 (s, 3H, CH3), 2.34 (s, 1H, 
OH, D2O exchangeable). 13C-NMR (CDCl3): δ (ppm) 
168.97 (C=O), 162.97 (C=O), 159.11 (C3), 151.60 (C3 
pyrazole), 137.90 (C5), 136.14 (N1-C1), 133.44, 131.80, 
130.47, 124.32, 117.92, 117.68, 116.38, 116.03, 
109.16, 108.88, 106.48. 
Synthesis of 5-((5-chloro-3-methyl-1-phenyl-1H-
pyrazol-4-yl)methylene)-2-(3,5-dinitrobenzoyl)-3-
phenyl-1,2-dihydro-1,2,4-triazin-6(5H)-one (13c): 
An equimolar quantity of (0.01 mol) 4-((5-chloro-3-
methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-2-
phenyloxazol-5(4H)-one, (0.01 mol) 3,5-
dinitrobenzohydrazide and (0.2 g) anhydrous sodium 
acetate in 15 mL glacial acetic acid was refluxed for 8-
10 h. The reaction mixture was poured into crushed ice 
and stirred. The crystals so obtained were filtered, 
washed with water, dried and recrystallized from 
ethanol. Yellow solid; Yield: 52 %; m.p.: 190-194 ºC; 
Rf: 0.71 (Toluene: Ethyl acetate: Formic acid (5:4:1)). 
IR (KBr) νmax (cm−1):  3210 (N-H, stretching), 3020 
(Aromatic C-H stretching), 2900 (Aliphatic C-H 
stretching), 1697 (C6=O), 1640 (C=N), 1515 (C=C), 
690 (C-Cl). 
1H-NMR (CDCl3): δ (ppm) 8.05-8.03 (d, 2H, CONH, 
Ar-H), 7.92-7.80 (m, 4H, Ar-H, CH=C), 7.78-7.48 (m, 
4H, Ar-H), 7.36-7.33 (d, 5H, Ar-H), 2.78 (s, 3H, CH3). 
13C-NMR (CDCl3): δ (ppm) 171.10 (C=O), 166.52 
(C=O), 158.25 (C3), 152.20 (C3 pyrazole), 147.72 (C5), 
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139.82 (N1-C1), 136.33, 131.59, 124.79, 121.58, 
117.81, 117.77, 116.39, 116.01, 109.24, 108.75, 
106.19. 
Synthesis of 2-benzoyl-5-((5-chloro-3-methyl-1-
phenyl-1H-pyrazol-4-yl)methylene)-3-phenyl-1,2-
dihydro-1,2,4-triazin-6(5H)-one (13d). Mol. formula: 
An equimolar quantity of (0.01 mol) 4-((5-chloro-3-
methyl-1-phenyl-1H-pyrazol-4-yl)methylene)-2-
phenyloxazol-5(4H)-one, (0.01 mol) benzohydrazide  
and (0.2 g) anhydrous sodium acetate in 15 mL glacial 
acetic acid was refluxed for 8-10 h. The reaction 
mixture was poured into crushed ice and stirred. The 
crystals so obtained were filtered, washed with water, 
dried and recrystallized from ethanol. Orange solid; 
Yield: 50 %; m.p.: 235-237 ºC; Rf: 0.70 (Toluene: 
Ethyl acetate: Formic acid (5:4:1)). IR (KBr) νmax 
(cm−1):  3200 (N-H, stretching), 3010 (Aromatic C-H 
stretching), 2890 (Aliphatic C-H stretching), 1699 
(C6=O), 1637 (C=N), 1523 (C=C), 690 (C-Cl). 1H-
NMR (CDCl3): δ (ppm) 8.03-8.01 (d, 2H, CONH, Ar-
H), 7.86-7.74 (m, 4H, Ar-H, CH=C), 7.60-7.38 (m, 6H, 
Ar-H), 7.34-7.31 (d, 5H, Ar-H), 2.79 (s, 3H, CH3). 13C-
NMR (CDCl3): δ (ppm) 169.01 (C=O), 163.08 (C=O), 
159.25 (C3), 151.02 (C3 pyrazole), 147.82 (C5), 139.92 
(N1-C1), 136.43, 130.59, 124.89, 121.58, 117.91, 
117.67, 116.39, 116.11, 109.14, 108.85, 106.39. 
Synthesis of 2-(2-naphthoyl)-5-((5-chloro-3-methyl-
1-phenyl-1H-pyrazol-4-yl)methylene)-3-phenyl-1,2-
dihydro-1,2,4-triazin-6(5H)-one (13e). An equimolar 
quantity of (0.01 mol) 4-((5-chloro-3-methyl-1-phenyl-
1H-pyrazol-4-yl)methylene)-2-phenyloxazol-5(4H)-
one, (0.01 mol) 2-naphthohydrazide  and (0.2 g) 
anhydrous sodium acetate in 15 mL glacial acetic acid 
was refluxed for 8-10 h. The reaction mixture was 
poured into crushed ice and stirred. The crystals so 
obtained were filtered, washed with water, dried and 
recrystallized from ethanol. Off Green solid; Yield: 60 
%; m.p.: 172-175 ºC; Rf: 0.61 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IR (KBr) νmax (cm−1):  3210 (N-
H, stretching), 3182 (Aromatic C-H stretching), 2999 
(Aliphatic C-H stretching), 1692 (C6=O), 1610 (C=N), 
1570 (C=C), 695 (C-Cl). 1H-NMR (CDCl3): δ (ppm) 
7.98-7.85 (m, 4H, CONH, Ar-H), 7.78 (s, 1H, CH=C), 
7.60-7.42 (m, 10H, Ar-H), 7.21 -7.12 (m, 3H, Ar-H), 
4.20 (s, 1H, Ar-H), 2.76 (s, 3H, CH3).13C-NMR 
(CDCl3): δ (ppm) 169.08 (C=O), 162.96 (C=O), 
159.09 (C3), 152.20 (C3 pyrazole), 144.69 (C5), 138.47 
(N1-C1), 137.90, 131.92, 131.80, 130.46, 124.32, 
121.93, 116.36, 116.03, 115.48, 106.50, 106.41.  
Synthesis of 5-((5-chloro-3-methyl-1-phenyl-1H-
pyrazol-4-yl)methylene)-2,3-diphenyl-1,2-dihydro-
1,2,4-triazin-6(5H)-one (13f): An equimolar quantity 
of (0.01 mol) 4-((5-chloro-3-methyl-1-phenyl-1H-
pyrazol-4-yl)methylene)-2-phenyloxazol-5(4H)-one, 
(0.01 mol) phenyl hydrazine and (0.2 g) anhydrous 
sodium acetate in 15 mL glacial acetic acid was 
refluxed for 8-10 h. The reaction mixture was poured 
into crushed ice and stirred. The crystals so obtained 
were filtered, washed with water, dried and 
recrystallized from ethanol. Dark orange solid; Yield: 
55 %; m.p.: 222-224 ºC; Rf: 0.78 (Toluene: Ethyl 
acetate: Formic acid (5:4:1)). IR (KBr) νmax (cm−1): 
3267 (N-H, stretching), 3057 (Aromatic C-H 
stretching), 2938 (Aliphatic C-H stretching), 1716 
(C=O), 1645 (C6=O), 1600 (C=N), 1537 (C=C), 689 
(C-Cl).  1H-NMR (CDCl3) (δ, ppm) 11.06 (s, 1H, 
CONH), 8.28-8.25 (d, 2H, Ar-H), 7.58-7.45 (m, 9H, 
Ar-H), 7.31 (s, 1H, CH=C), 7.01-6.95 (t, 2H, Ar-H), 
6.85-6.83 (d, 2H, Ar-H), 2.83 (s, 3H, CH3).13C-NMR 
(CDCl3): δ (ppm) 171.89 (C=O), 167.40 (C=O), 
160.67 (C3), 150.00 (C3 pyrazole), 149.69 (C5), 145.08 
(N1-C1), 143.91, 138.04, 131.33, 127.94, 123.76, 
12.16, 123.79, 116.11, 115.01, 113.72, 112.59, 111.27. 
Synthesis of 5-((5-chloro-3-methyl-1-phenyl-1H-
pyrazol-4-yl)methylene)-3-phenyl-1,2-dihydro-1,2,4-
triazin-6(5H)-one (13g): An equimolar quantity of 
(0.01 mol) 4-((5-chloro-3-methyl-1-phenyl-1H-
pyrazol-4-yl)methylene)-2-phenyloxazol-5(4H)-one, 
(0.01 mol) hydrazine hydrate  and (0.2 g) anhydrous 
sodium acetate in 15 mL glacial acetic acid was 
refluxed for 8-10 h. The reaction mixture was poured 
into crushed ice and stirred. The crystals so obtained 
were filtered, washed with water, dried and 
recrystallized from ethanol. Orange solid; Yield: 40 %; 
m.p.: 230-232 ºC; Rf: 0.73 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IR (KBr) νmax (cm−1):  3230 (N-
H, stretching), 3045 (Aromatic C-H stretching), 2930 
(Aliphatic C-H stretching), 1660 (C6=O), 1607 (C=N), 
1567 (C=C), 691 (C-Cl).  1H-NMR (CDCl3) (δ, ppm) 
11.11 (bs, 1H, CONH, D2O exchangeable), 8.62 (bs, 
1H, NH, D2O exchangeable), 8.10-8.07 (d, 2H, Ar-H), 
7.58-7.56 (d, 2H, Ar-H), 7.50-7.36 (m, 7H, Ar-H, 
CH=C), 2.35 (s, 3H, CH3). 13C-NMR (CDCl3): δ 
(ppm) 172.99 (C=O), 168.66 (C=O), 162.98 (C3), 
159.15 (C3 pyrazole), 147.07 (C5), 139.09 (N1-C1), 
137.89, 131.82, 130.49, 129.14, 127.60, 124.33, 
123.89, 119.95, 116.38, 116.04, 106.48. 
Synthesis of 5-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)-2-(4-nitrobenzoyl)-3-phenyl-1,2-
dihydro-1,2,4-triazin-6(5H)-one (18a): An equimolar 
quantity of (0.01 mol) 4-[(1,3-diphenyl-1H-pyrazol-4-
yl)methylidene]-2-phenyl-1,3-oxazol-5(4H)-one, (0.01 
mol) p-nitrobenzohydrazideand (0.2 g) anhydrous 
sodium acetate in 15 mL glacial acetic acid was 
refluxed for 8-10 h. The reaction mixture was poured 
into crushed ice and stirred. The crystals so obtained 
were filtered, washed with water, dried and 
recrystallized from ethanol. Color: Yellow solid; Yield: 
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52 %; m.p.: 268-270 ºC; Rf: 0.69 (Toluene: Ethyl 
acetate: Formic acid (5:4:1)). IR (KBr) νmax (cm−1): 
3276 (N-H, stretching), 3015 (Aromatic C-H 
stretching), 2929 (Aliphatic C-H stretching), 1711 
(C=O), 1642 (C6=O), 1608 (C=N), 1564 (C=C). 1H-
NMR (CDCl3) (δ, ppm) 9.37 (s, 1H, CONH), 9.27 (s, 
1H, C5-H), 8.21-8.18 (d, 2H, Ar-H), 7.99-7.95 (d, 2H, 
Ar-H), 7.86-7.84 (d, 2H, Ar-H), 7.73-7.71 (d, 2H, Ar-
H), 7.55-7.38 (m, 8H, Ar-H, CH=C), 7.36-7.29 (m, 4H, 
Ar-H). 13C-NMR (CDCl3): δ (ppm) 167.40 (C=O), 
160.67 (C=O), 150.00 (C3), 149.69 (C3 pyrazole), 
145.08 (C5), 143.91 (N1-C1), 138.04, 131.33, 127.94, 
123.76, 123.16, 116.11, 115.01, 113.72, 112.59, 
111.27, 106.25. 
Synthesis of 5-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)-2-(4-hydroxybenzoyl)-3-phenyl-1,2-
dihydro-1,2,4-triazin-6(5H)-one (18b): An equimolar 
quantity of (0.01 mol) 4-[(1,3-diphenyl-1H-pyrazol-4-
yl)methylidene]-2-phenyl-1,3-oxazol-5(4H)-one, (0.01 
mol) p-hydroxybenzohydrazide   and (0.2 g) anhydrous 
sodium acetate in 15 mL glacial acetic acid was 
refluxed for 8-10 h. The reaction mixture was poured 
into crushed ice and stirred. The crystals so obtained 
were filtered, washed with water, dried and 
recrystallized from ethanol. Orange solid; Yield: 80 %; 
m.p.: 250-252 ºC; Rf: 0.70 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IR (KBr) νmax (cm−1): 3292 (N-H, 
stretching), 3030 (Aromatic C-H stretching), 2920 
(Aliphatic C-H stretching), 1707 (C=O), 1638 (C6=O), 
1601 (C=N), 1560 (C=C).  1H-NMR (CDCl3) (δ, 
ppm) 9.43 (bs, 1H, CONH, D2O exchangeable), 9.28 
(s, 1H, C5-H), 8.27-8.25 (d, 2H, Ar-H), 7.90-7.87 (d, 
2H, Ar-H), 7.74-7.71 (d, 2H, Ar-H), 7.60-7.36 (m, 
11H, Ar-H), 6.99-6.95 (t, 1H, Ar-H), 6.83-6.81 (d, 2H, 
Ar-H), 6.58 (s, 1H, OH, D2O exchangeable). 13C-NMR 
(CDCl3): δ (ppm) 169.70 (C=O), 168.32 (C=O), 
149.81 (C3), 144.50 (C3 pyrazole), 142.98 (C5), 134.89 
(N1-C1), 132.19, 131.03, 128.97, 128.21, 127.58, 
122.88, 117.54, 113.90, 111.16. 
Synthesis of 2-(3,5-dinitrobenzoyl)-5-((1,3-diphenyl-
1H-pyrazol-4-yl)methylene)-3-phenyl-1,2-dihydro-
1,2,4-triazin-6(5H)-one (18c): An equimolar quantity 
of (0.01 mol) 4-[(1,3-diphenyl-1H-pyrazol-4-
yl)methylidene]-2-phenyl-1,3-oxazol-5(4H)-one, (0.01 
mol) 3,5-dinitrobenzohydrazideand (0.2 g) anhydrous 
sodium acetate in 15 mL glacial acetic acid was 
refluxed for 8-10 h. The reaction mixture was poured 
into crushed ice and stirred. The crystals so obtained 
were filtered, washed with water, dried and 
recrystallized from ethanol. Color: Yellow solid; Yield: 
52 %; m.p.: 273-274ºC; Rf: 0.68 (Toluene: Ethyl 
acetate: Formic acid (5:4:1)). IR (KBr) νmax (cm−1): 
3270 (N-H, stretching), 3005 (Aromatic C-H 
stretching), 2919 (Aliphatic C-H stretching), 1710 
(C=O), 1640 (C6=O), 1600 (C=N), 1560 (C=C). 1H-
NMR (CDCl3) (δ, ppm) 9.36 (s, 1H, CONH), 9.25 (s, 
1H, C5-H), 8.19-8.16 (d, 2H, Ar-H), 7.97-7.92 (d, 2H, 
Ar-H), 7.81-7.82 (d, 2H, Ar-H), 7.72-7.71 (d, 2H, Ar-
H), 7.52-7.37 (m, 7H, Ar-H, CH=C), 7.32-7.27 (m, 4H, 
Ar-H). 13C-NMR (CDCl3): δ (ppm)167.38 (C=O), 
160.65 (C=O), 150.01 (C3), 149.67 (C3 pyrazole), 
145.07 (C5), 143.89 (N1-C1), 138.08, 131.29, 127.90, 
123.74, 123.14, 116.09, 115.00, 113.69, 112.57, 
111.25, 106.15. 
Synthesis of 2-benzoyl-5-((1,3-diphenyl-1H-pyrazol-
4-yl)methylene)-3-phenyl-1,2-dihydro-1,2,4-triazin-
6(5H)-one (18d): An equimolar quantity of (0.01 mol) 
4-[(1,3-diphenyl-1H-pyrazol-4-yl)methylidene]-2-
phenyl-1,3-oxazol-5(4H)-one, (0.01 mol) 
benzohydrazide  and (0.2 g) anhydrous sodium acetate 
in 15 mL glacial acetic acid was refluxed for 8-10 h. 
The reaction mixture was poured into crushed ice and 
stirred. The crystals so obtained were filtered, washed 
with water, dried and recrystallized from ethanol. 
Orange solid; Yield: 35 %; m.p.: 270-274 ºC; Rf: 0.69 
(Toluene: Ethyl acetate: Formic acid (5:4:1)). IR (KBr) 
νmax (cm−1):  3258 (N-H, stretching), 2918 (Aromatic 
C-H stretching), 2851 (Aliphatic C-H stretching), 1726 
(C=O), 1670 (C6=O), 1624 (C=N), 1575 (C=C).1H-
NMR (CDCl3): δ (ppm) 9.26 (s, 1H, CONH), 9.12 (s, 
1H, CH-N), 8.01-7.99 (d, 2H, Ar-H), 7.85-7.78 (m, 4H, 
Ar-H, CH=C), 7.74-7.71 (d, 2H, Ar-H), 7.53-7.48 (m, 
10H, Ar-H), 7.40-7.36 (t, 3H, Ar-H). 13C-NMR 
(CDCl3): δ (ppm) 171.68 (C=O), 164.62 (C=O), 
158.77 (C3), 155.00 (C3pyrazole), 139.89 (C5), 139.77 
(N1-C1), 135.66, 133.14, 132.23, 130.76, 129.52, 
128.89, 128.81, 128.72, 128.60, 128.10, 127.77, 
127.29, 123.11, 119.81, 116.21. 
 
Synthesis of 2-(2-naphthoyl)-5-((1,3-diphenyl-1H-
pyrazol-4-yl)methylene)-3-phenyl-1,2-dihydro-1,2,4-
triazin-6(5H)-one (18e): An equimolar quantity of 
(0.01 mol) 4-[(1,3-diphenyl-1H-pyrazol-4-
yl)methylidene]-2-phenyl-1,3-oxazol-5(4H)-one (17), 
(0.01 mol) 2-naphthohydrazide and (0.2 g) anhydrous 
sodium acetate in 15 mL glacial acetic acid was 
refluxed for 8-10 h. The reaction mixture was poured 
into crushed ice and stirred. The crystals so obtained 
were filtered, washed with water, dried and 
recrystallized from ethanol. Orange solid; Yield: 40 %; 
m.p.: 250-252 ºC; Rf: 0.67 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IR (KBr) νmax (cm−1):  3300 (N-
H, stretching), 2980 (Aromatic C-H stretching), 2905 
(Aliphatic C-H stretching), 1723 (C=O), 1663 (C6=O), 
1600 (C=N), 1504 (C=C). 1H-NMR (CDCl3): δ (ppm) 
9.21 (s, 1H, CONH), 7.94-7.83 (m, 5H, Ar-H, CH-N), 
7.75-7.58 (m, 6H, Ar-H, CH=C), 7.55-7.37 (m, 7H, 
Ar-H), 7.26-7.17 (m, 4H, Ar-H), 4.20 (s, 2H, Ar-H). 
 
Asian Pac. J. Health Sci., 2019; 6(2):1-20                                              e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Verma et al                                    ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2019;6(2):1-20                                  14 
www.apjhs.com       
 
13C-NMR (CDCl3): δ (ppm) 184.98 (C=O), 179.90 
(C=O), 159.34 (C3), 142.31 (C3 pyrazole), 139.03 (C5), 
134.97 (N1-C1), 134.71, 134.12, 131.95, 131.29, 
130.72, 126.57, 126.03, 124.06, 120.62, 111.44. 
Synthesis of 5-((1,3-diphenyl-1H-pyrazzol-4-
yl)methylene)-2,3-diphenyl-1,2-dihydro-1,2,4-
triazin-6(5H)-one (18f): An equimolar quantity of 
(0.01 mol) 4-[(1,3-diphenyl-1H-pyrazol-4-
yl)methylidene]-2-phenyl-1,3-oxazol-5(4H)-one, (0.01 
mol) phenyl hydrazine and (0.2 g) anhydrous sodium 
acetate in 15 mL glacial acetic acid was refluxed for 8-
10 h. The reaction mixture was poured into crushed ice 
and stirred. The crystals so obtained were filtered, 
washed with water, dried and recrystallized from 
ethanol. Orange solid; Yield: 45 %; m.p.: 140 ºC; Rf: 
0.72 (Toluene: Ethyl acetate: Formic acid (5:4:1)). IR 
(KBr) νmax (cm−1): 3152 (N-H, stretching), 3055 
(Aromatic C-H stretching), 2855 (Aliphatic C-H 
stretching), 1642 (CONH), 1597 (C=N), 1556 (C=C). 
1H-NMR (CDCl3) (δ, ppm) 9.48 (s, 1H, CONH), 9.32 
(s, 1H, C5-H), 8.27-8.25 (d, 2H, Ar-H), 7.89-7.87 (d, 
2H, Ar-H), 7.74-7.71 (d, 2H, Ar-H), 7.66-7.36 (m, 
11H, 10 Ar-H, 1 CH=C), 7.28-7.20 (m, 1H, Ar-H), 
6.98-6.93(t, 1H, Ar-H), 6.82-6.76 (m, 2H, Ar-H). 13C-
NMR (CDCl3): δ (ppm) 172.50 (C=O), 159.10 (C3), 
156.65 (C3 pyrazole), 140.43 (C5), 140.27 (N1-C1), 
136.48, 134.34, 133.83, 131.56, 130.20, 129.99, 
129.96, 128.97, 128.70, 128.51, 127.57, 127.24, 
123.55, 119.58, 116.64. 
Synthesis of 5-((1,3-diphenyl-1H-pyrazol-4-
yl)methylene)-3-phenyl-1,2-dihydro-1,2,4-triazin-
6(5H)-one (18g): An equimolar quantity of (0.01 mol) 
4-[(1,3-diphenyl-1H-pyrazol-4-yl)methylidene]-2-
phenyl-1,3-oxazol-5(4H)-one, (0.01 mol) hydrazine 
hydrate  and (0.2 g) anhydrous sodium acetate in 15 
mL glacial acetic acid was refluxed for 8-10 h. The 
reaction mixture was poured into crushed ice and 
stirred. The crystals so obtained were filtered, washed 
with water, dried and recrystallized from ethanol. Buff 
yellow solid; Yield: 41 %; m.p.: 244-246 ºC; Rf: 0.74 
(Toluene: Ethyl acetate: Formic acid (5:4:1)). IR (KBr) 
νmax (cm−1): 3258 (N-H, stretching), 3037 (Aromatic C-
H stretching), 2920 (Aliphatic C-H stretching), 1648 
(C6=O), 1601 (C=N), 1556 (C=C). 1H-NMR (CDCl3) 
(δ, ppm) 9.43 (s, 1H, CONH), 9.23 (s, 1H, C5-H), 8.32 
(s, 1H, NH), 8.02-7.98 (d, 2H, Ar-H), 7.85-7.71 (m, 
6H, Ar-H), 7.63-7.38 (m, 8H, Ar-H, CH=C). 13C-NMR 
(CDCl3): δ (ppm) 169.88 (C=O), 158.88 (C3), 157.05 
(C3 pyrazole), 139.99 (C5), 139.54 (N1-C1), 135.11, 
133.98, 131.99, 130.66, 129.32, 128.54, 128.49, 
128.16, 127.91, 127.77, 127.54, 119.26, 116.32. 
Synthesis of 5-(furan-3-ylmethylene)-2-(4-
nitrobenzoyl)-3-phenyl-1,2-dihydro-1,2,4-triazin-
6(5H)-one (21a1): An equimolar quantity of (0.01 mol) 
4-(furan-2-ylmethylene)-2-phenyloxazol-5(4H)-one, 
(0.01 mol) p-nitrobenzohydrazide and (0.2 g) 
anhydrous sodium acetate in 15 mL glacial acetic acid 
was refluxed for 8-10 h. The reaction mixture was 
poured into crushed ice and stirred. The crystals so 
obtained were filtered, washed with water, dried and 
recrystallized from ethanol. Buff solid; Yield: 60.5 %; 
m.p.: 168-170 ºC; Rf: 0.61 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IR (KBr) νmax (cm−1): 3168 (N-H, 
stretching), 3010 (Aromatic C-H stretching), 2860 
(Aliphatic C-H stretching), 1634 (CONH), 1593 
(C=N), 1520 (C=C). 1H-NMR (CDCl3): δ (ppm) 8.27-
8.25 (d, 2H, Ar-H), 7.99-7.96 (d, 4H, Ar-H), 7.69 (s, 
1H, CONH), 7.62-7.61 (d, 1H, Ar-H), 7.57-7.42 (m, 
4H, Ar-H), 7.18 (s, 1H, CH=C), 6.66 (s, 1H, 3-furan). 
13C-NMR (75 MHz, CDCl3): δ 153.85 (C=O, benzoyl), 
147.41 (C6), 147.17 (C3), 145.34 (2’-Furan), 142.08 
(C5-furan), 129.06, 128.61, 126.07, 121.90. 
Synthesis of 5-(furan-3-ylmethylene)-2-(4-
hydroxybenzoyl)-3-phenyl-1,2-dihydro-1,2,4-
triazin-6(5H)-one (21a2). An equimolar quantity of 
(0.01 mol) 4-(furan-2-ylmethylene)-2-phenyloxazol-
5(4H)-one, (0.01 mol) p-hydroxybenzohydrazide and 
(0.2 g) anhydrous sodium acetate in 15 mL glacial 
acetic acid was refluxed for 8-10 h. The reaction 
mixture was poured into crushed ice and stirred. The 
crystals so obtained were filtered, washed with water, 
dried and recrystallized from ethanol. Green solid; 
Yield: 51.5 %; m.p.: 178-180 ºC; Rf: 0.69 (Toluene: 
Ethyl acetate: Formic acid (5:4:1)). IR (KBr) νmax 
(cm−1): 3145 (N-H, stretching), 3085 (Aromatic C-H 
stretching), 2855 (Aliphatic C-H stretching), 1633 
(CONH), 1540 (C=N), 1520 (C=C). 1H-NMR (CDCl3): 
δ (ppm) 8.97 (s, 3H, Ar-H), 7.729-7.696 (d, 3H, 
CONH, Ar-H), 7.50-7.30 (m, 7H, Ar-H), 6.38 (s, 1H, 
CH=C), 6.19 (s, 1H, 3- furan). 13C-NMR (75 MHz, 
CDCl3): δ 153.65 (C=O, benzoyl), 148.26 (C6), 148.06 
(C3), 136.26 (2’-Furan), 134.08 (C5-furan) 131.34, 
129.12, 128.70, 128.51, 125.23, 120.11. 
Synthesis of 2-(3,5-dinitrobenzoyl)-5-(furan-3-
ylmethylene)-3-phenyl-1,2-dihydro-1,2,4-triazin-
6(5H)-one (21a3): An equimolar quantity of (0.01 mol) 
4-(furan-2-ylmethylene)-2-phenyloxazol-5(4H)-one, 
(0.01 mol) 3,5-dinitrobenzohydrazide and (0.2 g) 
anhydrous sodium acetate in 15 mL glacial acetic acid 
was refluxed for 8-10 h. The reaction mixture was 
poured into crushed ice and stirred. The crystals so 
obtained were filtered, washed with water, dried and 
recrystallized from ethanol. Yellowish green solid; 
Yield: 50.6 %; m.p.: 170-172 ºC; Rf: 0.65 (Toluene: 
Ethyl acetate: Formic acid (5:4:1)). IR (KBr) νmax 
(cm−1): 3155 (N-H, stretching), 3093 (Aromatic C-H 
stretching), 2852 (Aliphatic C-H stretching), 1630 
(CONH), 1536 (C=N), 1516 (C=C). 1H-NMR (CDCl3): 
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δ (ppm) 8.97 (s, 3H, Ar-H), 7.729-7.696 (d, 3H, 
CONH, Ar-H), 7.50-7.36 (m, 5H, Ar-H), 6.38 (s, 1H, 
CH=C), 6.19 (s, 1H, 3- furan). 13C-NMR (75 MHz, 
CDCl3): δ 166.90 (C=O, benzoyl), 156.48 (C6), 153.98 
(C3), 151.42 (2’-Furan), 147.97 (C5-furan) 145.25, 
139.94, 131.57, 130.72, 123.77, 123.13, 120.32, 
118.79, 110.84. 
Synthesis of 2-benzoyl-5-(furan-3-ylmethylene)-3-
phenyl-1,2-dihydro-1,2,4-triazin-6(5H)-one(21a4): 
An equimolar quantity of (0.01 mol) 4-(furan-2-
ylmethylene)-2-phenyloxazol-5(4H)-one, (0.01 mol) 
benzohydrazide and (0.2 g) anhydrous sodium acetate 
in 15 mL glacial acetic acid was refluxed for 8-10 h. 
The reaction mixture was poured into crushed ice and 
stirred. The crystals so obtained were filtered, washed 
with water, dried and recrystallized from ethanol. Buff 
solid; Yield: 60 %; m.p.: 165-166 ºC; Rf: 0.60 
(Toluene: Ethyl acetate: Formic acid (5:4:1)). IR (KBr) 
νmax (cm−1): 3165 (N-H, stretching), 3005 (Aromatic C-
H stretching), 2855 (Aliphatic C-H stretching), 1630 
(CONH), 1590 (C=N), 1518 (C=C). 1H-NMR (CDCl3): 
δ (ppm) 8.24-8.21 (d, 2H, Ar-H), 8.10-7.99 (m, 6H, 
Ar-H), 7.68 (s, 1H, CONH), 7.61-7.60 (d, 1H, Ar-H), 
7.55-7.40 (m, 4H, Ar-H), 7.15 (s, 1H, CH=C), 6.64 (s, 
1H, 3-furan). 13C-NMR (75 MHz, CDCl3): δ 153.83 
(C=O, benzoyl), 147.31 (C6), 147.18 (C3), 144.33 (2’-
Furan), 141.08 (C5-furan), 128.06, 127.61, 127.07, 
122.90. 
Synthesis of 2-(2-naphthoyl)-5-(furan-3-
ylmethylene)-3-phenyl-1,2-dihydro-1,2,4-triazin-
6(5H)-one (21a5): An equimolar quantity of (0.01 mol) 
4-(furan-2-ylmethylene)-2-phenyloxazol-5(4H)-one, 
(0.01 mol) 2-naphthohydrazide and (0.2 g) anhydrous 
sodium acetate in 15 mL glacial acetic acid was 
refluxed for 8-10 h. The reaction mixture was poured 
into crushed ice and stirred. The crystals so obtained 
were filtered, washed with water, dried and 
recrystallized from ethanol. Brownish black; Yield: 80 
%; m.p.: 172–175 °C; Rf: 0.76 (Toluene: Ethyl acetate: 
Formic acid (5:4:1)). IR cm−1: 3176 (N-H), 3009 
(aromatic C-H), 2933 (aliphatic C-H), 1724 (CONH), 
1640 (C=O), 1580 (C=N, imine), 1525 (C=C). 1H-
NMR (300 MHz, CDCl3): δ (ppm) 10.29 (s, 1H, 
CONH, D2O exchangeable), 8.01–7.98 (d, 1H, J= 8.7 
Hz, Ar-H), 7.78–7.69 (m, 3H, Ar-H), 7.55 (s, 1H, 
CH=C), 7.44–7.3 (m, 4H, Ar-H), 7.32–7.28 (m, 3H, 
Ar-H), 7.16-7.05 (m, 4H, Ar-H), 6.52 (s, 1H, Ar-H), 
4.02 (s, 1H, CH=C).  13C-NMR (75 MHz, CDCl3): δ 
153.5 (C=O, benzoyl), 148.1 (C6), 135.3 (C3), 134.8 
(2’-Furan), 134.6 (C5-furan) 134.0, 131.9, 130.0, 129.3, 
128.6, 128.4, 128.2, 128.0, 127.8, 126.8, 126.5, 124.9, 
108.4. ESI-MS: m/z = 407.1264(M+), 408.1342(M+ + 
2); found: 407.13(M+), 408.13(M+ + 2). 
Synthesis of 2-(2-naphthoyl)-5-(4-hydroxy-3-
methoxybenzylidene)-3-phenyl-1,2-dihydro-1,2,4-
triazin-6(5H)-one (21b): An equimolar quantity of 
(0.01 mol) 4-(4-hydroxy-3-methoxybenzylidene)-2-
phenyloxazol-5(4H)-one, (0.01 mol) 2-
naphthohydrazideand (0.2 g) anhydrous sodium acetate 
in 15 mL glacial acetic acid was refluxed for 8-10 h. 
The reaction mixture was poured into crushed ice and 
stirred. The crystals so obtained were filtered, washed 
with water, dried and recrystallized from ethanol. Buff 
solid; Yield: 50 %; m.p.: 194-195 ºC; Rf: 0.70 
(Toluene: Ethyl acetate: Formic acid (5:4:1)). IR (KBr) 
νmax (cm−1): 3140 (N-H, stretching), 3010 (Aromatic C-
H stretching), 2844 (Aliphatic C-H stretching), 1624 
(CONH), 1590 (C=N), 1537 (C=C). 1H-NMR (CDCl3): 
δ (ppm) 8.18 (s, 1H, CONH), 7.98-7.74 (m, 6H, Ar-H), 
7.62-7.59 (d, 2H, Ar-H), 7.54-7.43 (m, 7H, Ar-H, 
CH=C), 7.18-7.08 (m, 1H, Ar-H), 4.17 (s, 1H, Ar-H), 
4.088 (s, 1H, OH), 3.95 (s, 3H, CH3). 13C-NMR (75 
MHz, CDCl3): δ 168.32 (C=O, benzoyl), 149.81 (C6), 
144.50 (C3), 142.98 (2’-Furan), 134.89 (C5-furan) 
132.19, 131.03, 128.97, 128.21, 127.58, 122.88, 
117.54, 113.90, 111.16. 
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